PB2324: USE OF COMBINATION OF THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH REFRACTORY/RELAPSED NON-HODGKIN LYMPHOMA: A PALLIATIVE CHEMOTHERAPY STRATEGY.

Ähnliche Einträge

• P1067: PHASE 2 STUDY OF ORAL THALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE FOR RECURRENT/REFRACTORY ADULT LANGERHANS CELL HISTIOCYTOSIS
  von: J.-N. Wang, et al.
  Veröffentlicht: (2022-06-01)
• Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
  von: Edvan De Queiroz Crusoe, et al.
  Veröffentlicht: (2020-04-01)
• PB2011: CHIDAMIDE COMBINED WITH THALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (TC2D) AS AN ORAL QUADRUPLET REGIMEN FOR RELAPSED/REFRACTORY MYELOMA PATIENTS: INITIAL RESULTS OF A PHASE IIA, MULTICENTER TRIAL
  von: Y. Li, et al.
  Veröffentlicht: (2022-06-01)
• Chidamide plus prednisone, cyclophosphamide, and thalidomide for relapsed or refractory peripheral T-cell lymphoma: A multicenter phase II trial
  von: Jinhua Liang, et al.
  Veröffentlicht: (2024-07-01)
• Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone
  von: Di Wang, et al.
  Veröffentlicht: (2021-01-01)